Journal of International Psychiatry

[Abstract] Objective: To explore the clinical effects of aripiprazole and risperidone in the treatment of schizophrenia. Methods: From October 2021 to October 2022, case data were collected and filed. The subjects were 100 schizophrenic patients admitted to the hospital. The subjects were divided into a control group (treated with risperidone) and an observation group (treated with aripiprazole) based on a standardized grouping process of "simple randomization method", with 50 cases each included; The clinical efficacy, incidence of adverse reactions, positive and negative symptom scale (PANSS) scores, glucose and lipid metabolism indicators, and serum prolactin levels were observed and compared between the two groups. Results There was no significant difference in the total effective rate between the two groups (P>0.05); Compared with before treatment, the PANSS scores of both groups decreased after treatment (P<0.05), and there was no significant difference between the two groups in terms of PANSS scores before and after treatment (P>0.05); The levels of TC, TG, and FPG in the control group after treatment were higher than those in the observation group before and during the same period of treatment (P; The serum prolactin levels in the control group increased at 4, 8, and 12 weeks of treatment, and were higher than those in the observation group (P; Comparison of the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Using risperidone and aripiprazole to treat schizophrenia has a comparable therapeutic effect and guaranteed safety, but aripiprazole has a relatively small impact on glycolipid metabolism and prolactin levels.

[Key words] Aripiprazole; Risperidone; Schizophrenia; Adverse reactions